Nahad Sedaghat Selected Research

COVID-19

1/2023	Third COVID-19 vaccine dose for people with multiple sclerosis who did not seroconvert following two doses of BBIBP-CorV (Sinopharm) inactivated vaccine: A pilot study on safety and immunogenicity.
1/2023	Effect of multiple sclerosis disease-modifying therapies on the real-world effectiveness of two doses of BBIBP-CorV (Sinopharm) vaccine.
12/2022	Detection of anti-NMDA receptor antibodies following BBIBP-CorV COVID-19 vaccination in a rituximab-treated person with multiple sclerosis presenting with manifestations of an acute relapse.
12/2022	Self-Reported safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among Iranian people with multiple sclerosis.
1/2022	SARS-CoV-2 serology among people with multiple sclerosis on disease-modifying therapies after BBIBP-CorV (Sinopharm) inactivated virus vaccination: Same story, different vaccine.
1/2022	Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: a practical review and meta-analysis.
10/2021	Acute relapse and poor immunization following COVID-19 vaccination in a rituximab-treated multiple sclerosis patient.
7/2021	Myasthenia gravis and coronavirus disease 2019: A report from Iran.
1/2021	Outcome of COVID-19 infection in multiple sclerosis patients receiving disease-modifying therapies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nahad Sedaghat Research Topics

Disease

9	COVID-19 01/2023 - 01/2021
9	Multiple Sclerosis 01/2023 - 01/2021
2	Myalgia 12/2022 - 10/2021
1	Critical Illness (Critically Ill) 01/2023
1	Multiple Trauma (Multiple Injuries) 01/2023
1	Anti-N-Methyl-D-Aspartate Receptor Encephalitis 12/2022
1	Ulcerative Colitis 12/2022
1	Autoimmune Diseases of the Nervous System 12/2022
1	Encephalitis (Encephalitis, Rasmussen) 12/2022
1	Disease Progression 11/2022
1	Hemorrhage 01/2022
1	Demyelinating Diseases (Demyelinating Disease) 01/2022
1	Candidiasis (Moniliasis) 01/2022
1	Autoimmune Diseases (Autoimmune Disease) 10/2021
1	Fatigue 10/2021
1	Infections 01/2021

Drug/Important Bio-Agent (IBA)

5	BIBP COVID-19 vaccineIBA 01/2023 - 01/2022
5	VaccinesIBA 01/2023 - 10/2021
4	COVID-19 VaccinesIBA 01/2023 - 10/2021
3	Fingolimod Hydrochloride (FTY720)FDA Link 01/2023 - 01/2022
2	Rituximab (Mabthera)FDA Link 12/2022 - 10/2021
1	C-Reactive ProteinIBA 01/2023
1	Inactivated VaccinesIBA 01/2023
1	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 12/2022
1	AntibodiesIBA 12/2022
1	Natalizumab (Tysabri)FDA Link 12/2022
1	Antiviral Agents (Antivirals)IBA 11/2022
1	CytokinesIBA 11/2022
1	Interferon-betaIBA 11/2022
1	Sphingosine-1-Phosphate ReceptorsIBA 01/2022
1	Messenger RNA (mRNA)IBA 01/2022
1	Tranexamic Acid (AMCA)FDA Link 01/2022
1	Chimeric Antigen ReceptorsIBA 01/2022
1	SteroidsIBA 10/2021

Therapy/Procedure

5	Therapeutics 01/2023 - 01/2021
1	Critical Care (Surgical Intensive Care) 01/2023
1	Injections 01/2023
1	Rhinoplasty 01/2022
1	Thymectomy 07/2021